Burkitt Lymphoma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkitt Lymphoma - Pipeline Review, H2 2016, provides an overview of the Burkitt Lymphoma (Oncology) pipeline landscape.

Burkitt lymphoma is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. Symptoms include fever, night sweats, swollen lymph nodes and weight loss. The disease is more common in males and people with compromised immune systems, such as those with HIV/AIDS. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkitt Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkitt Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkitt Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 13 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Burkitt Lymphoma.

Burkitt Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Burkitt Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkitt Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkitt Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkitt Lymphoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkitt Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkitt Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Burkitt Lymphoma Overview 8
Therapeutics Development 9
Pipeline Products for Burkitt Lymphoma - Overview 9
Pipeline Products for Burkitt Lymphoma - Comparative Analysis 10
Burkitt Lymphoma - Therapeutics under Development by Companies 11
Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 13
Burkitt Lymphoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Burkitt Lymphoma - Products under Development by Companies 16
Burkitt Lymphoma - Products under Investigation by Universities/Institutes 17
Burkitt Lymphoma - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
Arvinas, Inc. 19
bluebird bio, Inc. 20
Boehringer Ingelheim GmbH 21
Constellation Pharmaceuticals, Inc. 22
Immunomedics, Inc. 23
Karyopharm Therapeutics, Inc. 24
Millennium Pharmaceuticals Inc 25
Patrys Limited 26
Seattle Genetics, Inc. 27
Takeda Pharmaceutical Company Limited 28
Theravectys SA 29
Burkitt Lymphoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
19-3s - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
20-3s - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
alisertib - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ARV-825 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
bb-2121 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Cellular Immunotherapy to Target CD19 for ALL - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Cellular Immunotherapy to Target CD30 for Oncology - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
denintuzumab mafodotin - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
E1-3s - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Epstein-Barr virus vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ibrutinib - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ixazomib citrate - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
PATLM-1 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
selinexor - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
SH-7129 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
SH-7133 - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
SH-7139 - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
Small Molecules to Inhibit BET for Oncology - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
volasertib trihydrochloride - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Burkitt Lymphoma - Dormant Projects 122

Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables

Number of Products under Development for Burkitt Lymphoma, H2 2016 9
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Burkitt Lymphoma - Pipeline by AbbVie Inc, H2 2016 18
Burkitt Lymphoma - Pipeline by Arvinas, Inc., H2 2016 19
Burkitt Lymphoma - Pipeline by bluebird bio, Inc., H2 2016 20
Burkitt Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 21
Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 22
Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H2 2016 23
Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 24
Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 25
Burkitt Lymphoma - Pipeline by Patrys Limited, H2 2016 26
Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 27
Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 28
Burkitt Lymphoma - Pipeline by Theravectys SA, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Burkitt Lymphoma - Dormant Projects, H2 2016 122